-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

Benzinga·09/08/2026 12:15:52
Listen to the news
BMO Capital analyst Evan David Seigerman downgrades Amgen (NASDAQ:AMGN) from Outperform to Market Perform and maintains the price target from $450 to $450.